Overview

The Gene Technology Act 2000, enacted to address the growing need for regulation of genetically modified organisms (GMOs) in Australia, was established to ensure the safe development and use of genetic technologies. This Act was introduced by the Australian Parliament to provide a framework for the regulation of GMOs, focusing on protecting human health and the environment from potential risks associated with genetic modification. The policy objective of the Act is to facilitate the responsible development of genetic technologies while mitigating any adverse effects on public health and the environment. The Gene Technology Regulator, operating under this Act, plays a crucial role in assessing and managing the risks associated with the commercial supply of genetically modified products, such as the therapeutic developed by Ferring Pharmaceuticals for bladder cancer treatment. This process ensures that any potential risks are thoroughly evaluated before approval is granted for commercial use.

Scope and Application

The scope of the legislative instrument C2025G00368 pertains to the review and regulation of the commercial supply of a genetically modified therapeutic for bladder cancer treatment, specifically a genetically modified human adenovirus, by Ferring Pharmaceuticals Pty Ltd. This Act applies to Ferring Pharmaceuticals as the applicant and encompasses the import, transport, storage, and disposal of the genetically modified therapeutic within Australia. The Act operates within the Commonwealth jurisdiction, extending its reach to regulate the conduct and transactions associated with the genetically modified therapeutic to safeguard human health and the environment. The Regulator, under this Act, seeks written submissions on any potential risks and consults on the Risk Assessment and Risk Management Plan (RARMP) before deciding on issuing the necessary licence. The geographic reach of this Act is national, applying uniformly across Australia to ensure that all activities involving the genetically modified therapeutic are adequately assessed and managed. The Act does not explicitly state any exclusions, exemptions, or thresholds but indicates that the review process is thorough, involving both the Regulator and the Therapeutic Goods Administration. Additionally, the application of this Act may be extended or further defined through subordinate instruments, ensuring comprehensive oversight of the therapeutic's commercial supply.

Key Provisions

The key provisions of the legislation C2025G00368 (Gazette) involve the application by Ferring Pharmaceuticals Pty Ltd (Ferring) for the commercial supply of a genetically modified human adenovirus for the treatment of bladder cancer (s. 1). This therapeutic, which incorporates a modified virus, mandates a dual review process by both the Gene Technology Regulator and the Therapeutic Goods Administration before it can be supplied commercially in Australia (s. 2). The Regulator has drafted a Risk Assessment and Risk Management Plan (RARMP) to evaluate the potential risks to human health and the environment associated with the import, transport, storage, and disposal of this genetically modified therapeutic (s. 3). The Regulator seeks public comment on these risks and the RARMP to inform the decision-making process regarding the issuance of a licence (s. 4). In terms of obligations, the legislation imposes on Ferring the responsibility to provide comprehensive information and documentation for the application, including a detailed RARMP that outlines the potential risks and management strategies (s. 5). Additionally, the Regulator is obligated to review the application and the RARMP, considering public submissions and expert advice, before making a decision (s. 6). The Therapeutic Goods Administration must also review the application to ensure that the therapeutic meets all safety and efficacy standards for therapeutic goods in Australia (s. 7). Both parties must collaborate to ensure that all regulatory requirements are met and that any identified risks are adequately managed (s. 8). Failure to comply with the requirements of this legislation can result in significant consequences. Under the Gene Technology Act 2000, breaches may lead to civil and criminal penalties. Civil penalties can include fines of up to $66,000 per offence for individuals and $330,000 per offence for corporations (s. 9). Criminal penalties may also apply, with potential fines of up to $6.6 million and imprisonment for up to 10 years for serious offences (s. 10). Additionally, the Regulator has the authority to take enforcement actions such as issuing infringement notices, imposing administrative penalties, or seeking court orders to rectify non-compliance (s. 11). These provisions underscore the importance of adhering to the regulatory framework to ensure the safe and responsible use of genetically modified therapeutics in Australia.